Anthony Ware

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. His sixteen year tenure at Eli Lilly has included the clinical development, regulatory approval and launch of numerous novel therapeutics, including Taltz®, Olumiant®, Cymbalta®, Cialis®, Effient® and Trulicity®. Prior to Eli Lilly, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center. Before then, Dr. Ware was on the faculty of Harvard Medical School and also served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware currently serves as a member of the board of directors of AnaptysBio a NASDAQ-listed biotech company. Dr. Ware received a Bachelor of Science degree from Washburn University, a Medical Degree from the University of Kansas, has served in internships at the University of Texas at Houston and Baylor College of Medicine, and is board certified both in internal medicine and cardiovascular